Coagulation and Natural Anticoagulants » Coagulation Factors and Inhibitors

Abstract Number: PB0552

A Probable Therapeutic for a Child with Inherited Protein S Deficiency

V. Pereira¹, L. Thangada², M. khosla³, r. majumder⁴

Abstract Number: VPB0572

A study of the stability of fibrinogen and FXIII levels and microbial integrity of pooled cyroprecipitate stored at 1-6°C and 20-24°C for up to 120 hours

H. Kaur¹, A. Ang¹, S. Chua¹, P. Shu¹, C. Tan², W. Wong²

Abstract Number: OC 36.4

A Tethered Artificial Protease Reveals the Location of Key Regulatory Motifs in Factor V

F. Ayombil¹, R. Toso¹, R. Camire²

Abstract Number: PB0548

Abelacimab, a Factor XI/XIa Antibody Inhibits Clotting in Hemodialysis Circuits Ex Vivo

K. Kovacevic¹, C. Schörgenhofer², G. Langer², Y. Khder³, B. Jilma², J. Grafeneder⁴

Abstract Number: OC 65.2

Andexanet alfa is associated with a significant reduction in in-hospital mortality compared to 4F-PCC in a real-world analysis

P. Dobesh¹, C. Coleman², J. Ulloa³, B. Lovelace⁴, T. Dettling⁴, B. Koch⁴, G. Fermann⁵

Abstract Number: PB0547

Antithrombin deficiency is associated with more compact plasma fibrin clot structure and impaired susceptibility to fibrinolysis

A. Klajmon¹, M. Kopytek², J. Natorska³, A. Undas¹, M. Ząbczyk³

Abstract Number: VPB0570

Assessment of Impact of Metabolites of Edoxaban and Dabigatran on Fibrin and Thrombin Generation Assays

J. Evrard¹, R. Siriez¹, V. Maloteau¹, J. Dogné², J. Douxfils³

Abstract Number: PB0542

Bio-equivalence of Potency adjusted approved heparin solutions compared to a newly developed heparin solution.

E. Krupa¹, D. Hoppensteadt², W. Jeske¹, A. Farooqui¹, A. Kouta¹, O. Iqbal¹, B. Kantarcioglu³, R. Krämer⁴, J. Fareed²

Abstract Number: PB0561

Ca2+ and Zn2+ binding to human Protein Z (PZ) induces structural changes that augments its lipid binding

T. Sengupta¹, S. Gayathri², S. Gupta³

Abstract Number: PB0564

Combined Molecular Dynamics and Docking Studies on Direct Oral Anticoagulant Binding to Factor Xa Variants

D. Veizaj¹, D. Poole III², M. Schreuder³, P. Reitsma⁴, D. Verhoef⁴, D. Geerke⁵, M. Bos⁶

Abstract Number: PB0549

Comparative Studies on Clotting and Antiprotease Profile of Heparins of Ovine, Bovine and Porcine Origin

E. Krupa¹, J. Lewis², A. Farooqui¹, O. Iqbal¹, W. Jeske¹, J. Walenga¹, Y. Yao³, J. Fareed⁴

Abstract Number: VPB0567

Comparative Studies on the Interaction of Heparins from Various Origins with Heparin Cofactor II and Antithrombin

N. Baig¹, A. Kouta¹, M. Jaradeh², D. Hoppensteadt³, W. Jeske¹, J. Fareed³

Abstract Number: OC 67.4

Congenital factor VII deficiency in a large cohort of Portuguese patients — molecular profiling, pathogenicity stratification and genotype-phenotype correlation

C. Silva Pinto¹, I. Rocha², C. Catarino³, R. Salvado⁴, M. Costa⁵, F. Rodrigues⁶, S. Nobre Fernandes⁷, C. Geraldes⁸, T. Fidalgo⁹

Abstract Number: PB0532

Deciphering the role of small sulfated molecule PTS on AT3 structure and in vitro clot formation.

I. Ahmad¹, M. Abid², S. Deep³, M. Jairajpuri⁴

Abstract Number: PB0550

Differential Neutralization of Unfractionated Heparin and Enoxaparin by Andexanet Alfa

J. Lewis¹, O. Iqbal², W. Jeske², D. Hoppensteadt³, F. Siddiqui², B. Lewis², J. Fareed³

Abstract Number: PB0557

Effectiveness and safety of Direct Oral Anticoagulants (DOACs) in extremely obese compared to non-extremely obese patients in an observational prospective single-centre unselected patient registry

C. Moret Puig¹, S. Mojal², M. Plaza Seijas³, R. Acosta-Isaac⁴, J. Souto⁵

Abstract Number: PB0545

Efficacy and safety of Haemocer, a local hemostatic agent, in patients with congenital bleeding disorders: A pilot study

M. Karimi¹, S. Haghpanah², N. Javanmardi², H. Tavoosi³, S. Kamalian Fard², N. Momtahan²

Abstract Number: PB0538

Enzymatic activity of bound thrombin within fibrin fibers

J. Crossen¹, S. Diamond²

Abstract Number: VPB0569

Evaluation of the FibWave in Edoxaban and Healthy Samples, a Comparison with the APTT- and PT-based Clot Waveform Analysis

J. Evrard¹, R. Siriez¹, J. Dogné², J. Douxfils³

Abstract Number: PB0536

Ex vivo study of the concomitant use of plasma-derived Factor VIII/Von Willebrand Factor and emicizumab in patients with severe Hemophilia A

M. Bravo¹, A. Raventós¹, A. Pérez¹, E. Arias Salgado², M. Alvarez-Román³, N. Butta², V. Jiménez Yuste⁴, M. Costa¹, T. Willis⁵